{
  "meta": {
    "title": "43_Anti-Leprosy_Drugs",
    "url": "https://brainandscalpel.vercel.app/43-anti-leprosy-drugs-63750be5.html",
    "scrapedAt": "2025-11-30T12:34:27.467Z"
  },
  "questions": [
    {
      "text": "What is the mechanism of action of dapsone, considering that it is used in the treatment of leprosy, fungal infections and, also for immunomodulatory actions?",
      "choices": [
        {
          "id": 1,
          "text": "Cell wall synthesis inhibitor"
        },
        {
          "id": 2,
          "text": "Folic acid synthesis inhibitor"
        },
        {
          "id": 3,
          "text": "Protein synthesis inhibitor"
        },
        {
          "id": 4,
          "text": "Cell membrane inhibitor"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The mechanism of action of dapsone is<strong> inhibition of folic acid synthesis.</strong></p>\n<p>Dapsone [4,4‐diaminodiphenylsulphone&nbsp;(DDS)] is a structural analog of para-aminobenzoic acid (PABA)&nbsp;and a <strong>competitive inhibitor</strong> <strong>of dihydropteroate synthase</strong> in the folate pathway. It is <strong>weakly bactericidal </strong>and&nbsp;can cause mild hemolysis, and rarely anemia or psychosis.</p>\n<p><strong>DDS syndrome</strong>&nbsp;is a rare side effect of dapsone therapy in leprosy patients which&nbsp;starts <strong>after 5-6 weeks</strong>&nbsp;of starting&nbsp;dapsone&nbsp;and leads to exfoliative dermatitis, hepatosplenomegaly, lymphadenopathy, fever and hepatitis and may be fatal. It is also called '<strong>five-week dermatitis</strong>'.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7016",
      "difficulty": "medium"
    },
    {
      "text": "Dapsone would not be helpful in which of the following patients?",
      "choices": [
        {
          "id": 1,
          "text": "HIV positive patient with CD4<100 and IgG positive for Toxoplasma"
        },
        {
          "id": 2,
          "text": "An elderly man with pemphigoid"
        },
        {
          "id": 3,
          "text": "HIV positive patient with Pneumocystis jiroveci pneumonia"
        },
        {
          "id": 4,
          "text": "A child with schistosomiasis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Dapsone is not used in the treatment of <strong>schistosomiasis</strong>. Praziquantel is the drug recommended for this condition.</p>\n<p>Dapsone with pyrimethamine and leucovorin can be given for prophylaxis of Toxoplasma encephalitis in HIV patients with CD4&lt;100. Along with trimethoprim, it can be given for prophylaxis and treatment of Pneumocystis pneumonia. However, cotrimoxazole remains the drug of choice in both conditions.</p>\n<p>The <strong>uses of dapsone</strong> are:</p>\n<p>Infections </p>\n<ul>\n<li>Leprosy</li>\n<li><em>Pneumocystis jerovecii</em> infections (prophylaxis and treatment)</li>\n<li>Malaria</li>\n<li><em>Toxoplasma gondi</em> infections (prophylaxis)</li>\n</ul>\n<p>Inflammatory conditions </p>\n<ul>\n<li>Dermatitis herpetiformis</li>\n<li>Pemphigoid</li>\n<li>Relapsing chondritis</li>\n<li>Linear IgA bullous disease</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5254",
      "difficulty": "medium"
    },
    {
      "text": "What is the treatment of choice for the patient's condition depicted below?",
      "choices": [
        {
          "id": 1,
          "text": "Rifampicin + dapsone + cycloserine, for 12 months"
        },
        {
          "id": 2,
          "text": "Rifampicin + dapsone + clofazimine, for 6 months"
        },
        {
          "id": 3,
          "text": "Rifampicin + ofloxacin + minocycline, for 6 months"
        },
        {
          "id": 4,
          "text": "Rifampicin + dapsone + clofazimine, for 12 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given image of a man with <strong>nodular lesions </strong>on his face depicts<strong> lepromatous leprosy </strong>and<strong>&nbsp;</strong>is treated by <strong>standard multidrug regimen </strong>(MDR-WHO recommended)<strong> for 12 months.&nbsp;</strong></p>\n<p>It&nbsp;consists of:</p>\n<ul>\n<li><strong>Rifampicin</strong>: 600 mg once a month</li>\n<li><strong>Dapsone</strong>: 100 mg daily</li>\n<li><strong>Clofazimine</strong>: 300 mg once a month + 50 mg once daily</li>\n</ul><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/64763838666743d5aad6d65bd9304aac.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5257",
      "difficulty": "easy"
    },
    {
      "text": "All of the following are administered under supervision in India except?",
      "choices": [
        {
          "id": 1,
          "text": "Clofazimine"
        },
        {
          "id": 2,
          "text": "Pyrazinamide"
        },
        {
          "id": 3,
          "text": "Rifampicin"
        },
        {
          "id": 4,
          "text": "Dapsone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Dapsone </strong>is administered <strong>daily </strong>in both multibacillary and paucibacillary leprosy <strong>without supervision.</strong></p>\n<p><strong>Clofazimine</strong> is indicated as a <strong>once-monthly supervised </strong>dose (300 mg) and <strong>daily unsupervised</strong> doses (50 mg) in multibacillary leprosy and paucibacillary leprosy.</p>\n<p><strong>Pyrizanamide </strong>is an <strong>ATT drug</strong> which is administered under <strong>direct supervision</strong>.</p>\n<p><strong>Rifampicin</strong> is indicated as a <strong>once-monthly supervised </strong>dose for both multibacillary and paucibacillary leprosy.</p><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7777",
      "difficulty": "medium"
    },
    {
      "text": "A patient presented with multiple hypopigmented skin lesions and loss of sensation over the lesions. What is the most bactericidal drug for the condition?",
      "choices": [
        {
          "id": 1,
          "text": "Clofazimine"
        },
        {
          "id": 2,
          "text": "Dapsone"
        },
        {
          "id": 3,
          "text": "Rifampicin"
        },
        {
          "id": 4,
          "text": "Ethionamide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of <strong>leprosy </strong>and<strong>&nbsp;rifampicin </strong>is the <strong>most</strong>&nbsp;<strong>bactericidal</strong> anti-leprotic drug<strong>. </strong></p>\n<p>Clofazimine and dapsone are bacteriostatic agents, while ethionamide is not indicated in leprosy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5248",
      "difficulty": "easy"
    },
    {
      "text": "What is the most bactericidal anti leprotic drug amongst the given drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Amoxicillin"
        },
        {
          "id": 2,
          "text": "Ciprofloxacin"
        },
        {
          "id": 3,
          "text": "Ofloxacin"
        },
        {
          "id": 4,
          "text": "Erythromycin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ofloxacin</strong> is the most&nbsp;bactericidal anti leprotic drug amongst the given drugs.</p>\n<p>It exhibits high activity against <em>M. leprae</em>, and it is being used in <strong>alternative</strong> multidrug therapy (<strong>MDT</strong>) regimens in rifampicin-resistant cases.&nbsp;As a component of MDT, it has been found to hasten the bacteriological and clinical response.</p>\n<p>Among the macrolides, <strong>clarithromycin</strong> has activity against leprosy bacilli and is used for alternative MDT in cases resistant to both rifampicin and fluoroquinolones. Azithromycin shows activity against Mycobacterium avium complex but not lepra bacilli.</p>\n<p>Note: <strong>Rifampicin</strong> is the <strong>most potent</strong> bactericidal anti leprotic drug.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0821",
      "difficulty": "medium"
    },
    {
      "text": "Thalidomide is useful in the treatment of which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Downgrading reactions"
        },
        {
          "id": 2,
          "text": "Reversal reactions"
        },
        {
          "id": 3,
          "text": "Erythema nodosum leprosum"
        },
        {
          "id": 4,
          "text": "All of the above"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Thalidomide </strong>is useful in the treatment of <strong>erythema nodosum leprosum </strong>(ENL)&nbsp;or <strong>type 2 lepra</strong> <strong>reaction</strong>.&nbsp;It is indicated in <strong>recurring and persistent ENL lesions</strong> despite the completion of at least two courses of glucocorticoid therapy.</p>\n<p>Thalidomide is <strong>not effective </strong>in <strong>type 1</strong> <strong>lepra reaction.&nbsp;</strong>If type 1 reactions occur after initiation of antimycobacterial therapy, they are termed&nbsp;<strong>reversal reactions&nbsp;</strong>and it is histologically more tuberculoid. When they occur before the initiation, they are termed downgrading reactions and it is histologically more lepromatous.&nbsp;</p><hr><h3>Related Pearl: Lepra Reactions</h3><p><strong>Lepra Reactions:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type 1 Reaction</strong></p>\n<p>(Reversal/Upgrading)</p>\n</td>\n<td>\n<p><strong>Type 2 Reaction</strong></p>\n<p>(Erythema Nodosum Leprosum)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mainly seen in the&nbsp;<strong>Borderline</strong> spectrum (BT, BB, BL)</p>\n<p><strong>Most severe</strong> in Borderline Lepromatous(BL) leprosy</p>\n</td>\n<td>Mainly seen in <strong>LL</strong>(50%)&gt;BL(15%)</td>\n</tr>\n<tr>\n<td>\n<p>Usually seen <strong>within 12 months</strong> of initiation of Multidrug Therapy</p>\n</td>\n<td><strong>Unrelated</strong> to Multidrug therapy. May occur before, during or after treatment</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type 4</strong> Hypersensitivity</p>\n<p>Due to <strong>enhanced cell-mediated response</strong>&nbsp;increased destruction of bacilli following treatment in reversal</p>\n</td>\n<td>\n<p><strong>Type 3</strong> Hypersensitivity</p>\n<p>Primarily Humoral</p>\n<p>(<strong>Immune complex Deposition</strong> in tissues and vessels)</p>\n<p>Cytokine involved - <strong>TNF-&alpha;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inflammation of <strong>existing skin lesions</strong> (red, painful edematous skin lesions) that may <strong>ulcerate</strong></p>\n<p>New lesions may occur (rare)</p>\n<p><strong>Neuritis</strong>&nbsp;and <strong>Nerve abscesses&nbsp;</strong>(red, painful inflamed nerves)</p>\n</td>\n<td>\n<p><strong>New, erythematous and tender</strong>, subcutaneous and dermal nodules that are widely distributed over extremities and face</p>\n<p>Existing lesions do not change</p>\n</td>\n</tr>\n<tr>\n<td><strong>No</strong> systemic involvement</td>\n<td><strong>Systemic symptoms</strong> present - fever, myalgias, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis, lymphadenopathy</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment:</strong></p>\n<p>Supportive therapy for mild reactions with <strong>NSAIDs</strong></p>\n<p>In case of severe reactions with neuritis and eye lesions- <strong>Oral corticosteroids</strong></p>\n<p><strong>(Drug of Choice)</strong></p>\n<p>Nerve Abscess - Additional <strong>surgical drainage</strong></p>\n<p>Other drugs: Clofazimine, Cyclosporine</p>\n</td>\n<td>\n<p><strong>Treatment:</strong></p>\n<p><strong>Oral Corticosteroids - First-line drug<br /><br />Clofazimine </strong>(Steroid dependent ENL)<strong><br /></strong></p>\n<p><strong>Thalidomide -most effective </strong>but not used first due to various side effects</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5264",
      "difficulty": "medium"
    },
    {
      "text": "A patient with borderline leprosy develops severe type 1 lepra reaction during the course of his multidrug therapy. What would be the most appropriate treatment for him?",
      "choices": [
        {
          "id": 1,
          "text": "Glucocorticoids"
        },
        {
          "id": 2,
          "text": "Clofazimine"
        },
        {
          "id": 3,
          "text": "Thalidomide"
        },
        {
          "id": 4,
          "text": "Plasmapheresis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most appropriate therapy for <strong>severe type 1 lepra reactions</strong> is <strong>glucocorticoids. </strong></p>\n<p>Clofazimine, though effective in type 1 lepra reaction, is less efficacious than glucocorticoids.</p>\n<p>Thalidomide and plasmapheresis are&nbsp;not indicated in the treatment of type 1 lepra reaction.</p><hr><h3>Related Pearl: Lepra Reactions</h3><p><strong>Lepra Reactions:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type 1 Reaction</strong></p>\n<p>(Reversal/Upgrading)</p>\n</td>\n<td>\n<p><strong>Type 2 Reaction</strong></p>\n<p>(Erythema Nodosum Leprosum)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mainly seen in the&nbsp;<strong>Borderline</strong> spectrum (BT, BB, BL)</p>\n<p><strong>Most severe</strong> in Borderline Lepromatous(BL) leprosy</p>\n</td>\n<td>Mainly seen in <strong>LL</strong>(50%)&gt;BL(15%)</td>\n</tr>\n<tr>\n<td>\n<p>Usually seen <strong>within 12 months</strong> of initiation of Multidrug Therapy</p>\n</td>\n<td><strong>Unrelated</strong> to Multidrug therapy. May occur before, during or after treatment</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type 4</strong> Hypersensitivity</p>\n<p>Due to <strong>enhanced cell-mediated response</strong>&nbsp;increased destruction of bacilli following treatment in reversal</p>\n</td>\n<td>\n<p><strong>Type 3</strong> Hypersensitivity</p>\n<p>Primarily Humoral</p>\n<p>(<strong>Immune complex Deposition</strong> in tissues and vessels)</p>\n<p>Cytokine involved - <strong>TNF-&alpha;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inflammation of <strong>existing skin lesions</strong> (red, painful edematous skin lesions) that may <strong>ulcerate</strong></p>\n<p>New lesions may occur (rare)</p>\n<p><strong>Neuritis</strong>&nbsp;and <strong>Nerve abscesses&nbsp;</strong>(red, painful inflamed nerves)</p>\n</td>\n<td>\n<p><strong>New, erythematous and tender</strong>, subcutaneous and dermal nodules that are widely distributed over extremities and face</p>\n<p>Existing lesions do not change</p>\n</td>\n</tr>\n<tr>\n<td><strong>No</strong> systemic involvement</td>\n<td><strong>Systemic symptoms</strong> present - fever, myalgias, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis, lymphadenopathy</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment:</strong></p>\n<p>Supportive therapy for mild reactions with <strong>NSAIDs</strong></p>\n<p>In case of severe reactions with neuritis and eye lesions- <strong>Oral corticosteroids</strong></p>\n<p><strong>(Drug of Choice)</strong></p>\n<p>Nerve Abscess - Additional <strong>surgical drainage</strong></p>\n<p>Other drugs: Clofazimine, Cyclosporine</p>\n</td>\n<td>\n<p><strong>Treatment:</strong></p>\n<p><strong>Oral Corticosteroids - First-line drug<br /><br />Clofazimine </strong>(Steroid dependent ENL)<strong><br /></strong></p>\n<p><strong>Thalidomide -most effective </strong>but not used first due to various side effects</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5267",
      "difficulty": "easy"
    },
    {
      "text": "A patient with leprosy, who is on multidrug therapy, presents with painful raised lesions on his forehead as shown in the image. Which of the following must be avoided in his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Clofazimine"
        },
        {
          "id": 2,
          "text": "Corticosteroids"
        },
        {
          "id": 3,
          "text": "Thalidomide"
        },
        {
          "id": 4,
          "text": "Rifampicin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The presence of tender, erythematous, subcutaneous nodules as seen in the image is suggestive of&nbsp;<strong>Type II lepra reaction</strong>&nbsp;in which<strong>&nbsp;rifampicin</strong> must be avoided.&nbsp;</p>\n<p>Rifampicin is highly<strong> bactericidal</strong> to <em>M. leprae</em> and results in high kill rates and massive release of bacterial antigens and may<strong> aggravate </strong>type 2 lepra reactions (also called<strong> erythema nodosum leprosum</strong>). <strong>&nbsp;</strong></p>\n<p>Options A and B: Clofazimine and corticosteroids are indicated in both type 1 and type 2 lepra reactions.</p>\n<p>Option C: Thalidomide is indicated in type 2 lepra reactions.</p><hr><h3>Related Pearl: Lepra Reactions</h3><p><strong>Lepra Reactions:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type 1 Reaction</strong></p>\n<p>(Reversal/Upgrading)</p>\n</td>\n<td>\n<p><strong>Type 2 Reaction</strong></p>\n<p>(Erythema Nodosum Leprosum)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mainly seen in the&nbsp;<strong>Borderline</strong> spectrum (BT, BB, BL)</p>\n<p><strong>Most severe</strong> in Borderline Lepromatous(BL) leprosy</p>\n</td>\n<td>Mainly seen in <strong>LL</strong>(50%)&gt;BL(15%)</td>\n</tr>\n<tr>\n<td>\n<p>Usually seen <strong>within 12 months</strong> of initiation of Multidrug Therapy</p>\n</td>\n<td><strong>Unrelated</strong> to Multidrug therapy. May occur before, during or after treatment</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type 4</strong> Hypersensitivity</p>\n<p>Due to <strong>enhanced cell-mediated response</strong>&nbsp;increased destruction of bacilli following treatment in reversal</p>\n</td>\n<td>\n<p><strong>Type 3</strong> Hypersensitivity</p>\n<p>Primarily Humoral</p>\n<p>(<strong>Immune complex Deposition</strong> in tissues and vessels)</p>\n<p>Cytokine involved - <strong>TNF-&alpha;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inflammation of <strong>existing skin lesions</strong> (red, painful edematous skin lesions) that may <strong>ulcerate</strong></p>\n<p>New lesions may occur (rare)</p>\n<p><strong>Neuritis</strong>&nbsp;and <strong>Nerve abscesses&nbsp;</strong>(red, painful inflamed nerves)</p>\n</td>\n<td>\n<p><strong>New, erythematous and tender</strong>, subcutaneous and dermal nodules that are widely distributed over extremities and face</p>\n<p>Existing lesions do not change</p>\n</td>\n</tr>\n<tr>\n<td><strong>No</strong> systemic involvement</td>\n<td><strong>Systemic symptoms</strong> present - fever, myalgias, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis, lymphadenopathy</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment:</strong></p>\n<p>Supportive therapy for mild reactions with <strong>NSAIDs</strong></p>\n<p>In case of severe reactions with neuritis and eye lesions- <strong>Oral corticosteroids</strong></p>\n<p><strong>(Drug of Choice)</strong></p>\n<p>Nerve Abscess - Additional <strong>surgical drainage</strong></p>\n<p>Other drugs: Clofazimine, Cyclosporine</p>\n</td>\n<td>\n<p><strong>Treatment:</strong></p>\n<p><strong>Oral Corticosteroids - First-line drug<br /><br />Clofazimine </strong>(Steroid dependent ENL)<strong><br /></strong></p>\n<p><strong>Thalidomide -most effective </strong>but not used first due to various side effects</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/9069f1e296cf4b30a5d9119bd035a4a9.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3991",
      "difficulty": "medium"
    },
    {
      "text": "A patient presents with complaints of reddish-black discolouration of skin and body secretions. Which anti-mycobacterial agent can cause this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Clofazimine"
        },
        {
          "id": 2,
          "text": "Cycloserine"
        },
        {
          "id": 3,
          "text": "Capreomycin"
        },
        {
          "id": 4,
          "text": "Ciprofloxacin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Reddish-black discolouration </strong>of skin and body secretions is observed with the use of <strong>clofazimine.</strong></p>\n<p>Clofazimine has good penetration into many tissues and results in reddish-black discolouration of skin and body secretions. This may take a long time to resolve. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3990",
      "difficulty": "easy"
    },
    {
      "text": "Rifampin is not active against which of the following Mycobacterial species?",
      "choices": [
        {
          "id": 1,
          "text": "Mycobacterium avium complex"
        },
        {
          "id": 2,
          "text": "Mycobacterium leprae"
        },
        {
          "id": 3,
          "text": "Mycobacterium abscessus"
        },
        {
          "id": 4,
          "text": "Mycobacterium kansasii"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Rifampin</strong> is not active against<strong><em> Mycobacterium abscessus. </em></strong>It is&nbsp;<strong>innately resistant</strong> to rifampicin.</p>\n<p><strong>First-line therapy</strong> for<em> Mycobacterium abscessus</em>&nbsp;includes <strong>cefoxitin (or imipenem) + amikacin + clarithromycin</strong>.&nbsp;</p>\n<p>Rifampicin is effective against<em> Mycobacterium avium</em> complex, <em>Mycobacterium leprae,</em> and <em>Mycobacterium kansasii.</em>&nbsp;(Options A, B, D)</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4009",
      "difficulty": "medium"
    }
  ]
}